Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration-Reference-Cited by-同舟云学术

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

Published:2010-04 Issue:4 Volume:84 Page:332-336
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Ludek Pour,Hana Svachova,Zdenek Adam,Martina Almasi,Dana Kralova,Tomas Buchler,Lucie Kovarova,Marta Krejci,Jaroslav Michalek,Miroslav Penka,Jiri Vorlicek,Roman Hajek

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01396.x/fullpdf

Reference27 articles.

1. Bone marrow angiogenesis and progression in multiple myeloma;Vacca;Br J Haematol,1994

2. Prognostic value of bone marrow angiogenesis in multiple myeloma;Rajkumar;Clin Cancer Res,2000

3. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion;Neben;Br J Haematol,2001

4. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in muliple myeloma;Sezer;Eur J Haematol (Denmark),2001

5. Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma;Ščudla;Vnitr Lek,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The extracellular matrix: A key player in the pathogenesis of hematologic malignancies;Blood Reviews;2021-07

2. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo;PLOS ONE;2018-06-20

3. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma;Annals of Hematology;2017-03-23

4. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma;The American Journal of Pathology;2016-03

5. Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma;PLOS ONE;2015-06-26